Drug firm Lupin today said its subsidiary Gavis Pharmaceuticals has received final approval from the US health regulator to market potassium chloride extended release capsules, used for treating potassium deficiency in the bloodstream, in the American market.
US-based Gavis has received final approval from US Food and Drug Administration (USFDA) to market a generic equivalent of Actavis Labs FL Inc's potassium chloride extended release capsules in various strengths, Lupin Ltd said in a regulatory filing.
Lupin had announced acquisition of Somerset-based Gavis Pharmaceuticals on July 23 last year.
According to IMS MAT June sales data, potassium chloride extended-release capsules had US sales of USD 75.4 million.
Lupin stock closed at Rs 1,595.30, up 0.36 per cent, on BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
